EYEGENE

The current price of 185490 is 3135 KRW — it has decreased by 2.03% in the past 24 hours.

Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange EYEGENE stocks are traded under the ticker 185490.

185490 stock is 3.83% volatile and has beta coefficient of 1.29. Check out the list of the most volatile stocks — is EYEGENE there?

Yes, you can track EYEGENE financials in yearly and quarterly reports right on TradingView.

185490 stock has risen by 2.62% compared to the previous week, the month change is a 1.10% fall, over the last year EYEGENE has showed a 31.10% decrease.

185490 net income for the last quarter is ‪−4.76 B‬ KRW, while the quarter before that showed ‪−1.55 B‬ KRW of net income which accounts for −207.80% change. Track more EYEGENE financial stats to get the full picture.

No, 185490 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.

Like other stocks, 185490 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EYEGENE stock right from TradingView charts — choose your broker and connect to your account.

185490 reached its all-time high on Sep 1, 2021 with the price of 60200 KRW, and its all-time low was 2800 KRW and was reached on Dec 5, 2023.
See other stocks reaching their highest and lowest prices.

As of Apr 24, 2024, the company has 88.00 employees. See our rating of the largest employees — is EYEGENE on this list?

Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EYEGENE technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EYEGENE stock shows the sell signal. See more of EYEGENE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.

EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EYEGENE EBITDA is ‪−24.95 B‬ KRW, and current EBITDA margin is −798.26%. See more stats in EYEGENE financial statements.